fluorine f 18 sodium fluoride positron emission tomography in evaluating response to dasatinib in patients with prostate cancer and bone metastases

Conditions: Hormone-Resistant Prostate Cancer; Metastatic Malignant Neoplasm in the Bone; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer

Summary: this phase ii trial is studying how well fluorine f 18 sodium fluoride positron emission tomography (pet) works in evaluating response to dasatinib in patients with prostate cancer and bone metastases. diagnostic procedures, such as fluorine f 18 sodium fluoride pet, may help doctors predict a patient's response to treatment and help plan the best treatment.

primary objectives: i. determine if changes in regional fluoride incorporation, measured by 18f-fluoride pet (suv and ki), occur in both castration-resistant prostate cancer bone metastases and normal bone as a response to treatment with dasatinib. secondary objectives: i. determine if changes in 18f-fluoride transport (k1), an indicator of blood flow, and therefore, an indirect marker of angiogenesis, occur in both castration-resistant prostate cancer bone metastases and normal bone as a response to treatment with dasatinib. outline: this is a multicenter study. patients undergo fluorine f 18 sodium fluoride pet scan at baseline and then at 12 weeks after initiation of treatment with dasatinib. pet parameters (suv, ki, and kl) are also analyzed.

Eligibility criteria:
inclusion criteria: * must be able to provide a written informed consent * men 18 years or older with metastatic castration-resistant prostate cancer enrolling onto the febbo clinical trial with dasatinib therapy (must meet all inclusion criteria for dasatinib treatment study and comply with requirements of that specific clinical trial) * histologic confirmation of original prostate cancer diagnosis * presence of at least one convincing bone metastasis as defined by bone scintigraphy, computed tomography (ct) scan (magnetic resonance imaging \[mri\] if indicated), or plain x-ray * must currently have castrate testosterone levels (\< 50 ng/dl) from orchiectomy or maintenance on a luteinizing hormone-releasing hormone (lhrh) agonist or lhrh antagonist exclusion criteria: * on the nilutamide-only arm (arm a of the clinical therapeutic trial) * note: however, if a patient crosses-over from nilutamide at the time of progression to add dasatinib therapy, he may be eligible for 18f-fluoride pet imaging protocol if he meets all inclusion criteria for this trial * any condition that would alter the patient's mental status, prohibiting the basic understanding and/or authorization of informed consent * a serious underlying medical condition that would otherwise impair the patient's ability to receive treatment and imaging studies * expected lifespan of 12 weeks or less * extremely poor intravenous access, prohibiting the placement of a peripheral iv line for injection of radiotracer * initiation of bisphosphonate therapy less than 4 weeks from the first pet scan * radiation treatment to bone less than 4 weeks from first pet scan * radiopharmaceutical treatment to bone less than 4 weeks from first pet scan * treatment with granulocyte-macrophage colony stimulating factor (gm-csf) or granulocyte csf (g-csf) within 4 weeks prior to first pet scan * inability to lie still for the imaging * weight \> 300 lbs. (due to equipment specifications)